122 related articles for article (PubMed ID: 2073870)
1. Reduction of urinary albumin excretion by thromboxane synthetase inhibitor, OKY-046, through modulating renal prostaglandins in patients with diabetic nephropathy.
Tajiri Y; Inoguchi T; Umeda F; Nawata H
Diabetes Res Clin Pract; 1990; 10(3):231-9. PubMed ID: 2073870
[TBL] [Abstract][Full Text] [Related]
2. Prostaglandins and diabetic nephropathy.
Umeda F; Kuroki T; Nawata H
J Diabetes Complications; 1995; 9(4):334-6. PubMed ID: 8573760
[TBL] [Abstract][Full Text] [Related]
3. Effects of captopril on urinary excretion of albumin and prostaglandins in patients with diabetic nephropathy.
Tajiri Y; Umeda F; Inoguchi T; Kunisaki M; Nawata H; Ninomiya H; Asano T
Diabetes Res; 1990 Mar; 13(3):145-50. PubMed ID: 2091882
[TBL] [Abstract][Full Text] [Related]
4. Effects of thromboxane synthetase inhibitor (OKY-046) on urinary prostaglandin excretion and renal function in streptozotocin-induced diabetic rat.
Tajiri Y; Umeda F; Inoguchi T; Nawata H
J Diabetes Complications; 1994; 8(2):126-32. PubMed ID: 8061349
[TBL] [Abstract][Full Text] [Related]
5. Improvement of renal function with a selective thromboxane A2 synthetase inhibitor, DP-1904, in lupus nephritis.
Yoshida T; Kameda H; Ichikawa Y; Tojo T; Homma M
J Rheumatol; 1996 Oct; 23(10):1719-24. PubMed ID: 8895147
[TBL] [Abstract][Full Text] [Related]
6. The effect of a thromboxane synthetase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin F1 alpha in patients with ischemic cerebrovascular disease.
Uyama O; Nagatsuka K; Nakabayashi S; Isaka Y; Yoneda S; Kimura K; Abe H
Stroke; 1985; 16(2):241-4. PubMed ID: 3883580
[TBL] [Abstract][Full Text] [Related]
7. Abnormal prostanoid metabolism in lupus nephritis and the effects of a thromboxane A2 synthetase inhibitor, DP-1904.
Yoshida T; Ichikawa Y; Tojo T; Homma M
Lupus; 1996 Apr; 5(2):129-38. PubMed ID: 8743126
[TBL] [Abstract][Full Text] [Related]
8. Role for thromboxane A2 from glomerular thrombi in nephropathy with type 2 diabetic rats.
Okumura M; Imanishi M; Okamura M; Hosoi M; Okada N; Konishi Y; Morikawa T; Miura K; Nakatani T; Fujii S
Life Sci; 2003 May; 72(24):2695-705. PubMed ID: 12679187
[TBL] [Abstract][Full Text] [Related]
9. Effects of cilostazol, a phosphodiesterase inhibitor, on urinary excretion of albumin and prostaglandins in non-insulin-dependent diabetic patients.
Watanabe J; Sako Y; Umeda F; Nawata H
Diabetes Res Clin Pract; 1993; 22(1):53-9. PubMed ID: 8137717
[TBL] [Abstract][Full Text] [Related]
10. Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus.
Patrono C; Ciabattoni G; Remuzzi G; Gotti E; Bombardieri S; Di Munno O; Tartarelli G; Cinotti GA; Simonetti BM; Pierucci A
J Clin Invest; 1985 Sep; 76(3):1011-8. PubMed ID: 3900132
[TBL] [Abstract][Full Text] [Related]
11. Glomerular prostaglandin and thromboxane synthesis in rat nephrotoxic serum nephritis. Effects on renal hemodynamics.
Lianos EA; Andres GA; Dunn MJ
J Clin Invest; 1983 Oct; 72(4):1439-48. PubMed ID: 6685136
[TBL] [Abstract][Full Text] [Related]
12. Clinical effects of selective thromboxane A2 synthetase inhibitor in patients with nephrotic syndrome.
Niwa T; Maeda K; Shibata M; Yamada K
Clin Nephrol; 1988 Nov; 30(5):276-81. PubMed ID: 3214971
[TBL] [Abstract][Full Text] [Related]
13. Effects of a selective thromboxane synthetase inhibitor OKY-046 on experimental diabetic nephropathy.
Hora K; Oguchi H; Furukawa T; Hora K; Tokunaga S
Nephron; 1990; 56(3):297-305. PubMed ID: 2077412
[TBL] [Abstract][Full Text] [Related]
14. Renal production of thromboxane and prostaglandins in a rat model of type 2 diabetes.
Okumura M; Imanishi M; Yamashita T; Yamamura Y; Kim S; Iwao H; Tanaka S; Fujii S
Life Sci; 2000; 66(5):371-7. PubMed ID: 10670825
[TBL] [Abstract][Full Text] [Related]
15. [Beneficial effect of a selective TXA2 synthetase inhibitor, OKY-046, both on thromboxane B2 production and vascular damage after spinal cord injury in rat spinal cord].
Morimoto K; Ikata T; Tounai T
Nihon Seikeigeka Gakkai Zasshi; 1990 Jan; 64(1):82-8. PubMed ID: 2319197
[TBL] [Abstract][Full Text] [Related]
16. Rabbit nephrotoxic nephritis: effect of a thromboxane synthetase inhibitor on evolution and prostaglandin excretion.
Shinkai Y; Cameron JS
Nephron; 1987; 47(3):211-9. PubMed ID: 3317092
[TBL] [Abstract][Full Text] [Related]
17. Renal hemodynamics and urinary excretion of 6-keto-prostaglandin F1 alpha and thromboxane B2 in newly diagnosed type I diabetic patients.
Gambardella S; Andreani D; Cancelli A; Di Mario U; Cardamone I; Stirati G; Cinotti GA; Pugliese F
Diabetes; 1988 Aug; 37(8):1044-8. PubMed ID: 3391343
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of thromboxane synthetase by OKY-1581 stimulates the formation of PGE2, PGF2 alpha, PGD2 and 6-keto-PGF1 alpha in human platelets.
Uotila P; Matintalo M
Prostaglandins Leukot Med; 1984 Apr; 14(1):41-6. PubMed ID: 6427791
[TBL] [Abstract][Full Text] [Related]
19. Chronic thromboxane inhibition preserves function of rejecting rat renal allografts.
Coffman TM; Ruiz P; Sanfilippo F; Klotman PE
Kidney Int; 1989 Jan; 35(1):24-30. PubMed ID: 2651752
[TBL] [Abstract][Full Text] [Related]
20. Effect of acute thromboxane A2 inhibition on the renal hemodynamics in a spontaneously non-insulin-dependent diabetic rat, Otsuka Long-Evans Tokushima Fatty rat.
Uriu K; Kaizu K; Qie YL; Kai K; Eto S
J Diabetes Complications; 1999; 13(4):182-6. PubMed ID: 10616856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
